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Altered expression of many genes and proteins is essential for cancer development and
progression. Recently, the affected expression of metadherin (MTDH), also known as
AEG-1 (Astrocyte Elevated Gene 1) and Lyric, has been implicated in various aspects
of cancer progression and metastasis. Elevated expression of MTDH/AEG-1 has been
reported in many cancers including breast, prostate, liver, and esophageal cancers,
whereas its expression is low or absent in non-malignant tissues. These expression
studies suggest that MTDH may represent a potential tumor associated antigen. MTDH
also regulates multiple signaling pathways including PI3K/Akt, NF-κB, Wnt/β-catenin,
and MAPK which cooperate to promote the tumorigenic and metastatic potential of
transformed cells. Several microRNA have also been found to be associated with the
increased MTDH expression in different cancers. Increased MTDH levels were linked to
the tumor chemoresistance making it an attractive novel therapeutic target. In this review,
we summarize data on MTDH function in various cancers.
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INTRODUCTION
Advances in cancer prevention and early diagnosis significantly improved the cancer
treatment outcomes. Still, cancers remain one of the most challenging global healthcare.
Approximately 18 million new cancer cases and 9.6 million malignancy related deaths were
expected in 2018 (1). One of the major challenges in cancer therapy is its specificity, where only
cancers become affected without injuring the healthy cells. Therefore, advances in identification of
tumor antigens are essential for targeting exclusively tumor cells. Tumor antigens are classified
as tumor specific, tumor associated and cancer testis antigens (2). Tumor associated antigens
(TAA) are over-expressed in tumors and these can be used as immunotherapeutic targets. In the
effort of identification of this targets, 15 Astrocyte Elevated Genes have been characterized, of
which metadherin (MTDH) was shown to be the most relevant to tumorigenesis. MTDH, also
known as Astrocyte Elevated Gene-1(AEG-1) or LYRIC (Lysine Rich CEACAM1), is a putative
TAA (3–5). MTDH was identified by in vivo phage display screening as a protein which was
responsible for the breast to lung cancer metastasis possessing extracellular domain called lung
homing domain (4). Further investigations revealed MTDH expression in various cancer types
capable of metastasis (3–5).
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There are two MTDH isoforms coded on chromosome
eight. Amplification of 8q22, including the MTDH locus is
associated with chemoresistance and metastasis in aggressive
breast cancer (6). Multiple cancer associated mutations in
the MTDH gene (Figure 1A) are reported in the COSMIC
database (7). Furthermore, altered expression, copy number and
mutations of MTDH (Figure 1B) have been identified in many
cancer types as reported in the cBIO database (8). There is
increasing evidence in functional interactions of MTDH and
important pro-oncogenic pathways, including MYC-mediated
processes (Figure 2). It appears that the main role of MTDH is
associated with tumor chemoresistance and metastasis (6). Here
we present an overview of the MTDH expression and function in
various cancers as well as its potential as an intrinsic treatment
modulating agent.
FIGURE 1 | (A) Cancer-related Metadherin mutations (https://cancer.sanger.ac.uk/cosmic) (B) Metadherin mutations in many cancer types. The results was
generated by the TCGA Research Network (http://www.cbioportal.org/).
MTDH REGULATION AND
MOLECULAR FUNCTIONS
MTDH is a type-two transmembrane protein containing an
extracellular lung homing domain which is implicated in
breast cancer metastasis to the lung (4). MTDH encodes a
single-pass transmembrane protein with the molecular mass of
64-kDa expressed mainly in the endoplasmic reticulum and
perinuclear space (5). In polarized epithelial cells, it colocalizes
with tight junction protein ZO-1 and occludin (3); however
MTDH is not a native component of tight junctions but
become incorporated during tight junction complex maturation.
The sub-cellular location of MTDH protein varies depending
upon physiological state of the cell (9). In non-malignant
tissue, MTDH was shown expressed in the nucleus, whereas in
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FIGURE 2 | Molecular pathways of Metadherin generated by GeneMANIA
Cytoscape plugin (https://genemania.org/).
malignant cells it becomes translocated into the cytoplasm (10).
It is believed that cytoplasmic translocation of MTDH promotes
disease progression by mediating mechanisms that support pro-
angiogenesic and metastatic pathways.
It appears that TNF-α is the key regulator of MTDH
expression. TNF-α upregulates MTDH expression via NF-
κB pathways. TNF-α causes NF-κB nuclear translocation and
consequent interaction with MTDH, which is essential for
activation of downstream genes (11). The N-terminal domain of
MTDH interacts with NF-κB and triggers gene expression via
several convergent mechanisms (9). NF-κB nuclear translocation
coincides with a significant reduction of IκBα level, suggesting
MTDH involvement in IκBα degradation. Studies have also
revealed that MTDH interacts with Cyclic AMP-responsive
element binding protein–binding protein (CBP) which is a
NF-κB coactivator (9, 12). Hence, MTDH may function as a
bridging element among p50–p65, NF-κB, CBP, and the basal
transcription machinery and therefore consequent induction of
NF-κB related gene expression enhances migration and invasion
(9) (Figure 3). MTDH promoted NF-κB gene expression results
in anchorage independent cell growth (10), possibly mediated
by direct activation of matrix metalloproteinase 1 (MMP1)
expression (13). MTDH also serves as a link between NF-
κB and matrix metalloprotease 9 (MMP9) expression (14,
15).The role of MTDH/AEG-1 as an endoplasmic reticulum
(ER)-associated cytoplasmic RNA binding protein has been
recently reported by Meng et al. (16) where MTDH/AEG-1
was also found in complex with other RNA binding proteins.
More recently Hsu et al. (17) identified the MTDH/AEG-
1: RNA interactome using unbiased genome wide methods
including HITS-CLIP (high-throughput sequencing of RNA
isolated by crosslinking immunoprecipitation) and PAR-CLIP
(photoactivatable ribonucleoside-enhanced crosslinking and
immunoprecipitation) which revealed that the MTDH/AEG-
1 RNA interactome includes the organelle protein-encoding
transcripts as well as secretory and cytosolic protein-encoding
mRNAs (17).
MTDH EXPRESSION AND FUNCTION
IN CANCER
MTDH is involved in multiple cancer associated cellular
signaling pathways, most notably in the context of this review,
pro-angiogenesis and pro-metastasis pathways (Figure 3,
Table 1). MTDH/AEG-1 promotes cell survival, inhibits
apoptosis, and promotes tumor progression via multiple
PI3K/Akt pathways (18). Emdad et al. (19) further showed
that MTDH/AEG-1 promotes an invasive phenotype and
angiogenesis via PI3K-Akt. The potential role of MTDH
in angiogenesis is related to its functional link to vascular
endothelial growth factor (VEGF), IGFBP7, and epithelial–
mesenchymal transition (EMT) markers. It was shown that
MTDH increases VEGF expression via the PI3K/Akt pathway
in head and neck squamous cell (20). MTDH is also associated
with expression of the E-cadherin, β-catenin, snail, and N-
cadherin epithelial-mesenchymal transition (EMT) markers in
hepatocellular carcinoma cells (21). There is also evidence of a
functional link between MTDH and pro-survival mechanisms
mediated by the lymphoid enhancer binding factor 1 (LEF-
1) and GSK3β components of the Wnt/β-catenin pathway
in chronic lymphocytic leukemia (22) and hepatocellular
carcinoma (23). Elevated expression of MTDH in hepatocellular
carcinoma results in the up-regulation of multiple genes and
signaling pathways such as the activation of ERK 42/44 and
p38 Mitogen Activated Protein Kinase (MAPK) signaling
pathway (24). Activation of ERK 42/44 and p38MAPK enhanced
GSK3β phosphorylation which in turn drives β-catenin nuclear
translocation and thereby activate Wnt signaling (24).
Also, MTDH/AEG-1 can up regulate Claudin 4 (CLDN4) and
tetraspanin which enhance cell invasion (23). Chen et al. have
shown that the increased expression ofMTDH/AEG-1 frequently
overserved in hepatocellular carcinoma downregulates
expression of the IGFB7 tumor suppressor and thereby
contributes to cancer progression (25). It has also been shown
that the knockdown of MTDH causes increased sensitivity to
Panobinostat (LBH589) and tumor necrosis factor-a-related
apoptosis-inducing ligand (TRAIL) combination treatment.
As TRAIL can trigger apoptosis in cancer cells and LBH589
augments the sensitivity of cancer cells to TRAIL induced
apoptosis. It can be inferred that over expression of MTDH may
negatively influence apoptosis and cell cycle checkpoints and
thereby promote cell survival (26).
CLINICAL SIGNIFICANCE OF MTDH
EXPRESSION IN CANCER
MTDH was shown to be expressed in ductal carcinoma in
situ (DCIS) of the breast (27). Increased MTDH expression
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FIGURE 3 | Molecular interactions between MTDH/AEG-1 and various effector molecules of signal transduction pathways exhibiting different biological functions.
is also implicated in prostate cancer (10, 28). Also MTDH
functionally interacts with the Ha-Ras oncogene and leads
to tumor development and progression in melanocytes (5).
Expression of MTDH is implicated in breast cancer stem
cell (CSC) growth and tumor resistance to paclitaxel and
trastuzumab (29–32). Elevated expression of MTDH was also
reported in salivary gland tumors and is associated with
poorer outcomes (33). Increased expression of MTDH is
also implicated in hepatocellular carcinoma recurrence and
metastasis which remains one of five most commonly diagnosed
cancers worldwide, largely attributable to chronic viral hepatitis
(HBV, HCV), and alcoholism (20, 34–36). Increased MTDH
expression is also associated with mechanisms of metastasis in
colorectal cancer (CRC) (15, 37) including activation of MMP9.
Increased MTDH is also associated with AKT/PI3K mediated
mechanisms of metastasis in head and neck squamous cell
carcinoma (HNSCC) patients (38). The significance of MTDH
regulation of cancer growth was confirmed using miRNA-
375 and MTDH knockdown experiments in HNSCC model
(35). MTDH can regulate the cancer cell metastasis by actin
cytoskeletal remodeling in gastric and non-small cell lung cancer
(39, 40). Accordingly, the downregulation of MTDH expression
could induce remodeling of the actin cytoskeleton and inhibit
epithelial-mesenchymal transition in gastric cancer cell lines
(MKN45 and AGS) (39).
ROLE OF INCREASED MTDH EXPRESSION
IN TREATMENT RESISTANCE
Many mechanisms of anticancer drug resistance have been
described in cancer cells and have been reviewed elsewhere
recently (41, 42). There is a strong evidence linking MTDH
expression to the resistance to multiple cancer therapeutics,
including tamoxifen, trastuzumab, and paclitaxel (6, 16, 30, 31,
43, 44).Chemo-resistance in MTDH expressing cells was shown
associated with activation of autophagy. Autophagy related
mechanisms were shown to protect tumor cells from metabolic
stress caused by the anticancer drugs cisplatin and paclitaxel
(45). Experimental suppression of MTDH lead to an increased
sensitivity to doxorubicin in cancer cells (46–48). These MTDH
targeting therapeutic approaches could applied not only to treat
cancer, but also to prevent, reverse or delay the chemo resistance.
MICRO RNAs REGULATION OF
MTDH EXPRESSION
It is well-established that micro-RNAs (miRs) play important, if
subtle, roles in the regulation of gene expression and translation
in cellular differentiation and proliferation. Unsurprisingly,
aberrant expression of oncogenic miRs (onco-miRs) and tumor
suppressor miRs is implicated in cancer pathogenesis (49, 50).
MTDH regulates expression of miRs and in turn is also regulated
by miRs (Figure 4). MTDH knockdown inhibits angiogenetic
properties of the MDA-MB-231 breast cancer cell line, which
is mediated by downregulation of the oncomir miR-21 (51). In
contrast, reduction in miR-630 expression results in increased
MTDH expression in breast cancer (52) (Figure 4). Expression of
miR-145 is lost in high-grade serous ovarian carcinoma resulting
in an increased expression of MTDH (53) (Figure 4). Loss
of activity of the p53 tumor suppressor results in decreased
or loss of miR-145 expression, contributing to an increased
MTDH levels (53). Similarly, miR-342-3p functions as a tumor
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suppressor by targeting MTDH in human osteosarcoma (54) and
prostate cancer (55). Expression of miR-26a regulates MTDH
TABLE 1 | MTDH containing gene ontologies.
GENE ONTOLOGIES
Molecular Functions
GO:0000988:transcription factor activity, protein binding
GO:0000989:transcription factor activity, transcription factor binding
GO:0001085:RNA polymerase II transcription factor binding
GO:0003712:transcription cofactor activity
GO:0003713:transcription coactivator activity
GO:0003723:RNA binding
GO:0003725:double-stranded RNA binding
GO:0008134:transcription factor binding
GO:0044822:poly(A) RNA binding
GO:0051059:NF-kappaB binding
Cellular Components
GO:0005635:nuclear envelope
GO:0005923:bicellular tight junction
GO:0016324:apical plasma membrane
GO:0016604:nuclear body
GO:0031965:nuclear membrane
GO:0043296:apical junction complex
GO:0045177:apical part of cell
GO:0046581:intercellular canaliculus
GO:0048471:perinuclear region of cytoplasm
GO:0070160:occluding junction
Molecular Functions
GO:0007043:cell-cell junction assembly
GO:0010508:positive regulation of autophagy
GO:0031663:lipopolysaccharide-mediated signaling pathway
GO:0043297:apical junction assembly
GO:0045766:positive regulation of angiogenesis
GO:0051092:positive regulation of NF-kappaB transcription factor activity
GO:0051896:regulation of protein kinase B signaling
GO:0051897:positive regulation of protein kinase B signaling
GO:0070830:bicellular tight junction assembly
GO:1904018:positive regulation of vasculature development
levels, where the loss of miR-26a in triple negative breast
cancer cells (TNBC) leads to increased MTDH and acts as a
prognostic marker for breast cancer outcome (56) (Figure 4).
Similarly, upregulation of MTDH in gastric cancer may occur
as a consequence of reduced miR-22 expression. Moreover, miR-
22 can prevent gastric cancer cell proliferation and invasion,
suggesting its potential therapeutic efficacy (57) (Figure 4). Thus,
it can be concluded that miRNAs are crucially involved in
regulation of MTDH expression in malignancies.
MTDH AS A POTENTIAL TARGET FOR
CANCER THERAPEUTICS
MTDH plays an important role in progression and metastasis of
many cancers. Although the understanding of the MTDH cancer
promoting mechanisms is incomplete, there is a compelling
evidence that MTDH regulates multiple signaling pathways
which cooperate to promote the tumorigenic and metastatic
potential of transformed cells. Additionally there is new
evidence suggesting that functional inhibition ofMTDH function
could be the novel approach to treat cancer. For example,
MTDH in breast cancer down regulates expression of the
PTEN (Phosphatase and tensin homolog) tumor suppressor
via NF-κB mediated pathways and contributes to the HER2-
targeting therapy resistance (31). Thus, MTDH may represent
an interesting therapeutic target for treatment of HER2+
breast cancers. For example, Bortezomib, is an FDA-approved
proteasome inhibitor used in multiple myeloma treatment
and acts (in part) by reducing MTDH activity (58). Studies
have further demonstrated that RNAi-mediated knockdown of
MTDH reduces angiogenesis by down regulating the ERK1/2
signaling (51).
Immunotherapy targeting the tumor antigens has been an
area of intense research. Expression of MTDH is increased
in many different cancer types. Importantly, auto-antibodies
against the MTDH protein have been detected in cancer patients
confirming its immunogenicity and supports MDTH as a
potential immunotherapy target (59). We recently identified
FIGURE 4 | Key cancer related miRNAs that regulate the expression of MTDH in different types of cancer cells.
Frontiers in Oncology | www.frontiersin.org 5 May 2019 | Volume 9 | Article 349
Dhiman et al. Metadherin Expression in Cancer
three T-cell epitopes within the MTDH protein supporting its
potential value as a cancer vaccine target (60). Consistent with
this a DNA vaccine designed to induce an anti-MTDH CD8+
mediated immune response inhibited cancer cell proliferation
and lung metastases in a mouse breast cancer xenograft model
(47). Given that MTDH/AEG-1 expression is increased in many
cancer types and proof of principle experiments support it
as an effective immunotherapy target, further research is now
warranted to test such treatments efficacy in advanced preclinical
cancer models.
CONCLUSION
MTDH is pro-oncogenic factor playing multifaceted and diverse
roles in cancer progression. Its association and central role in
regulating signaling pathways such a MAPK, wnt/β-catenin,
PI3K/AkT, NF-κβ pathways in various cancers shows that it
plays a vital role in metastasis. MTDH contribution to chemo
and radiotherapy resistance provides a new direction for the
development of anticancer therapeutics. Multiple mechanisms
converge to promote expression of MTDH in cancers. Further
studies are therefore warranted to determine whether the
elevatedMTDH expression has prognostic value for development
of the malignancy. Given its increased expression in many
cancer types it would be important to determine whether
MTDH represents a feasible target for cancer therapy, including
immune-therapy. For these reasons there is now an urgent need
to determine the clinical and therapeutic significance of increased
MTDH expression in cancer.
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